The FDA has accepted for review the sBLA for Afrezza (insulin human) inhalation powder in children and adolescents with type 1 or 2 diabetes.
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA ...
This drug, marketed for other uses, is drawing young adults into devastating addictions -and sometimes fatal consequences.
Aptar Digital Health's HeroTracker® Sense has been granted by the U.S Food and Drug Administration 510(k) clearance as a ...
October 21, 2025 - Nanoform Finland Plc (“Nanoform”), a leading nanoparticle medicine performance-enhancing company, today announced that key findings from two proof-of-concept studies conducted in ...
Phase II trial shows belzutifan effectively shrinks rare neuroendocrine tumors and improves symptoms, offering hope for ...
Aquastar Corp. has recalled multiple brands of frozen raw shrimp due to possible exposure to very low levels of radioactive ...
MannKind (MNKD) announced that the U.S. Food and Drug Administration, FDA, has accepted the supplemental biologics license application, sBLA, ...
Cannabidiol (CBD) can calm two critical immune pathways that drive neuroinflammation in Alzheimer's disease, according to a ...
The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
You've probably smelled it at the club or in the pit of a concert, but you better wise up, because it's back on the wider club scene.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback